urticarial rash
Recently Published Documents


TOTAL DOCUMENTS

49
(FIVE YEARS 24)

H-INDEX

8
(FIVE YEARS 3)

2021 ◽  
Vol 14 (9) ◽  
pp. e244763
Author(s):  
Helena Luís ◽  
Carolina Barros ◽  
Diogo André ◽  
Alexandra Malheiro

A 70-year-old man was admitted to our COVID-19 ward with thoracalgia, productive mucus cough, fatigue and erythematous–violaceous macules on the inner side of feet and interdigital regions. The patient was started on oxygen and dexamethasone. On the day of discharge, he maintained the skin changes despite the resolution of COVID-19 symptoms. A 57-year-old woman initially presented with diffuse urticarial rash on the cervical and chest region. Oral cetirizine was started, and pruritus improved. Thirty days after the discharge, the patient maintained the rash, but without pruritus. A 49-year-old man was admitted with thoracalgia, shortness of breath, dry cough and urticarial rash on the cervical and chest region. The patient was treated with cetirizine. The pruritus improved, and 5 days after discharge, the urticarial areas completely disappeared.


2021 ◽  
Vol 26 (3) ◽  
pp. 46-50
Author(s):  
Kh. P. Derevyanko ◽  
L. N. Khusainova ◽  
M. M. Khafizov ◽  
A. Sh. Sattarova ◽  
Sh. M. Safin

The new coronavirus SARS-CoV-2 is a single-stranded RNA virus of the Coronaviridae family and is clinically manifest with respiratory symptoms. However, patients have been described with symptoms and complications from the nervous system, as well as skin manifestations in the form of various rashes. In our clinical case of coronavirus infection (SARS-CoV-2), this is pneumonia with respiratory failure of the 1st degree, moderate severity and Bell’s palsy in combination with skin rashes in the form of an urticarial rash in a 58-year-old woman. Clinical features of cutaneous and neurological symptoms were prior to the development of respiratory symptoms. The presented clinical case showed that COVID-19, before the development of respiratory symptoms, can manifest itself with peripheral paralysis of the facial nerve and be combined with skin rashes, which can complicate the timely diagnosis of a viral disease.


2021 ◽  
Vol 104 (7) ◽  
pp. 1214-1217

The authors report a case of a 32-year-old Thai woman with a COVID-19 infection that presented with urticaria and angioedema with a pityriasis rosea (PR)-like rash at a private hospital in Thailand. She presented at the hospital with bloody nasal discharge and diarrhea but without fever, myalgia, or any respiratory symptoms. She complained of angioedema and PR-like lesions on the third day of the treatment. Urticarial rash appeared intermittently for four weeks after all medications were discontinued, during which the patient had no fever, no respiratory symptoms, or any other symptoms. However, the RT-PCR results for COVID-19 RNA were positive during the time that the urticarial symptoms persisted. The COVID-19 RNA became negative on the fourth day after the last urticarial episode. Urticarial rash may be a clue that the inflammatory process is activated by COVID-19 virus after the treatment is completed. Keywords: Cutaneous; Pityriasis rosea; Angioedema; Urticaria; COVID-19


Author(s):  
Paola FACHERIS ◽  
Andrea D’ARINO ◽  
Giulia PAVIA ◽  
Mario VALENTI ◽  
Giacomo M. GUIDELLI ◽  
...  

2021 ◽  
Vol 14 (3) ◽  
pp. e241793
Author(s):  
Sandeep Pagali ◽  
Riddhi S Parikh

A 54-year-old woman presented with pruritic rash and hives of 3 days’ duration followed by shortness of breath for 1 day. SARS-CoV-2 PCR test for COVID-19 was positive. Cutaneous manifestations of COVID-19 include acral lesions, urticarial rash, erythematous maculopapular rash, vascular rashes and vesicular rash. The cutaneous manifestations are mostly described as self-limiting. Urticarial rashes are not reported as the initial presentation symptom of COVID-19 infection but mostly noted to occur at the same time or after the onset of non-cutaneous symptoms. Management of cutaneous manifestations of COVID-19 affecting quality of life has not been well studied. Antihistamine therapy is the primary recommended therapy. Role of antiviral therapy for severe cases of rash needs to be further assessed.


Author(s):  
Danni Liang ◽  
Svetlana Lvovich ◽  
Nicholas Kuzma
Keyword(s):  

2021 ◽  
pp. 63-64
Author(s):  
Santosh Kondekar ◽  
Tanya Manish Arickatt ◽  
Anushri Soni

Nearly 9 months into the COVID-19 pandemic, the patients of SARS-CoV-2 infection have presented with various clinical manifestations, including dermatological manifestations which are less common. The dermatological ndings which are non-progressive and clinically insignicant are easily missed as they are not reported to a dermatologist, especially when they are the only manifestation of SARS-CoV-2 infection. It is important to understand the signicance of these rashes as some of the immunological events can have complications like Kawasaki disease. Hereby we present a case of a SARS-CoV-2 positive child who presented with urticarial rash following 5 days of SARS-CoV-2 infection


Author(s):  
Iwona Dziewa ◽  
Timothy Hahn ◽  
Neeti Bhardwaj

We presented the case of a 1-month-old girl with diffuse urticarial-like rash since birth. The initial evaluation showed elevated inflammatory markers. The response to treatment helped to narrow the diagnosis. In this case, we explored the differential diagnosis of rashes in this age group and the role of a therapeutic trial of medication as a diagnostic modality.


2021 ◽  
Vol 10 (3) ◽  
pp. 298
Author(s):  
Martina Burlando ◽  
Astrid Herzum ◽  
Emanuele Cozzani ◽  
Aurora Parodi

Sign in / Sign up

Export Citation Format

Share Document